Incyte (INCY) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.12% |
| Dec 31, 2025 | 108.17% |
| Sep 30, 2025 | 24.25% |
| Jun 30, 2025 | -44.69% |
| Mar 31, 2025 | 18.35% |
| Dec 31, 2024 | 23.76% |
| Sep 30, 2024 | 2.10% |
| Jun 30, 2024 | -85.88% |
| Mar 31, 2024 | -0.34% |
| Dec 31, 2023 | -16.26% |
| Sep 30, 2023 | -12.66% |
| Jun 30, 2023 | 55.75% |
| Mar 31, 2023 | -91.19% |
| Dec 31, 2022 | 25.71% |
| Sep 30, 2022 | -17.81% |
| Jun 30, 2022 | 14.56% |
| Mar 31, 2022 | 21.84% |
| Dec 31, 2021 | 0.03% |
| Sep 30, 2021 | 17.04% |
| Jun 30, 2021 | 22.42% |
| Mar 31, 2021 | 3.17% |
| Dec 31, 2020 | -26.29% |
| Sep 30, 2020 | 94.10% |
| Jun 30, 2020 | 73.72% |
| Mar 31, 2020 | -91.73% |
| Dec 31, 2019 | 13.24% |
| Sep 30, 2019 | 68.97% |
| Jun 30, 2019 | 42.39% |
| Mar 31, 2019 | 42.57% |
| Dec 31, 2018 | -23.62% |
| Sep 30, 2018 | 67.53% |
| Jun 30, 2018 | 45.28% |
| Mar 31, 2018 | -16.24% |
| Dec 31, 2017 | -72.36% |
| Sep 30, 2017 | 107.64% |
| Jun 30, 2017 | 28.48% |
| Mar 31, 2017 | -47.71% |
| Dec 31, 2016 | 28.37% |
| Sep 30, 2016 | 31.80% |
| Jun 30, 2016 | -55.37% |
| Mar 31, 2016 | 40.11% |
| Dec 31, 2015 | 21.04% |
| Sep 30, 2015 | 17.52% |
| Jun 30, 2015 | 13.84% |
| Mar 31, 2015 | 7.53% |